RE:posted this too earlyI consider myself lucky to have been able to attend one of the meetings (Road show) last week and came away feeling extremely positive that we are indeed sitting on something extremely special. So special that we get someone of Mark’s caliber to turn down other job offers and take a pay cut because he can see the big picture of the gold mine he is now sitting on. We now have the precise employees to get this moved to the next level (and quickly). We have Mark Day new CEO/Lead scientist , Catherine London IR/PR, a great new board (with extreme connections and prior history of tremendous stock growth for new biotech companies) and a phenomenal SAB that has an inherit understanding of the direction the science has to take for quickest adoption by various big pharmas (thus driving stock price).
The execution to this point in time may have not been the greatest (in hindsight such things are always easy to disparage) I would consider the issue to be one of naivet on the part of previous management and not one of malice as has been construed by some. I believe that the negotiations were simply conducted with the wrong echelon of employees at the pharmas that we are dealing with (Mark Day brings to the table the ability to access the CEOs of the appropriate companies instead of having to deal with middle management, who in tern then have to try to sell the idea upstream to the top management while in direct competition with thousands of other ideas that are also vying for one of the lucky spots that actually will get funding and attention.) Mark will now have buy in from the highest level (These CEOs will simply be able to dictate that a new program will be executed on)
The main reasons that this will now move forward at an ever accelerating rate is that Mark has a very precise vision and plan on how to move the science forward in a manner that drug companies require (first come the monkeys, etc) With his complete understanding of the path and trajectories required (he has done this and has been responsible for hundreds of programs getting approved and moved through the various clinical stages in order to get a drug to final completion). Mark not only understands what we need to do in order to get a drug from point A to Point B, he has a very clear-cut understanding of how to structure a drug trial in the proper way that is required and demanded by the pharma that is looking to acquire the technology (this was certainly missing up to this point).
Going forward, it will be of paramount importance to follow up each achievement, milestone, achieved goals, etc, with news releases and great press, and this is were Catherine London’s background, contacts and experience will pay of in magnificent ways. (She has contacts at big pharma, national news and press all over the USA) She will be able to get publications that we have all dreamed of involved at the appropriate times after we hit goals and make deals) I can already see the stock move in ways that we have all been hoping and dreaming of.
Too recap, I think that we now have the right people with the proper skill sets and impressive contacts to move this company in consequential ways that will propel the stock up and forward to the levels that it and we deserve. (I can only imagine what will happen when we get on Nasdaq) The company is considerably undervalued at this time and will be even more so once the first results from monkeys are available. Exciting times are ahead and we should all enjoy the ride that has just started.
fixing formatting issue